Experience of the Raz Procedure for Stress Urinary Incontinence / 대한비뇨기과학회지

We retrospectively evaluated the 20 patients who underwent the Raz operation for genuine stress urinary incontinence from January, 1993 to January, 1994. The mean periods of follow-up was 11.1+/-4.3 months. Four patients with grade I stress incontinence, twelve patients with grade II stress incontinence and four patients with grade III stress incontinence underwent the Raz bladder neck suspension. All patients had no previous anti-incontinence operation. Seventeen patients(85%) were cured, while two patients(10%) were significantly improved with only rare episodes of incontinence not requiring protection. One(5%) was failure. When the results were stratified by degree of incontinence preoperatively 4 of 4 patients(100%) with mild, 11 of 12(9l.7%) with moderate and 4 of 4(100%) with severe incontinence had a successful outcome. Namely, 95 percent of the patients were either cured or improved. The complications were not significant except temporary urinary retention of 2 to 20 days, there was no permanent urinary retention. The advantages of a needle suspension procedure, as compared with the abdominal retropubic techniques, include simplicity, less operative time, decreased postoperative morbidity, and a shorter hospital stay, because it avoids an extensive abdominal operation. In addition, the vaginal approach enables the surgeon to perform concomitant pelvic floor surgery for other conditions, such as cystocele, rectocele, enterocele, and uterine prolapse. Therefore, in a relatively short-term follow-up and a small group, Raz bladder neck suspension seems to be the ideal procedure for the woman presenting with stress urinary incontinence.

Effects of Doxazosin Mesylate in Patients with Benign Prostatic Hyperplasia / 대한비뇨기과학회지

The clinical effect of doxazosin mesylate, a selective long acting alpha-1 adrenergic blocker, were evaluated in 31 patients with symptomatic benign prostatic hyperplasia ranging from 49- 85 years old. All patients underwent a urodynamic evaluation and symptom score checking before enrollment into the study. The dose of doxazosin was 2mg per day. And the mean duration of treatment was 157 days. 31 patients were followed on doxazosin for 3 to 12 months with mean 7.5 months. The adverse drug reactions were observed only 1 case. The parameters used to assess the effectiveness of doxazosin included peak and mean urinary flow rates, micturition symptom scores and residual urine, and global assessment by the patient The peak and mean urinary flow rates increased by 77% and 86%, respectively. The obstructive and irritative symptom scores were improved by 51% and 41% respectively. The improvements in urinary flow rates and symptom scores were maintained for this interval. Although this preliminary experience with doxazosin is encouraging, the ultimate role of doxazosin for the long term treatment of benign prostatic hyperplasia needs further evaluation.